

## Pharsight Expands **REGULATORY OFFERINGS** and Teams Up with CRI

Pharsight has expanded its reporting and analysis services (RAS) offerings to include two new business units: preclinical and statistics and data management. Both units are overseen by John Murphy, Dr.P.H., senior VP of consulting services.

Pharsight's RAS business, launched in April 2007, performs regulatory clinical pharmacokinetics/pharmacodynamics (PK/PD) reporting and analysis.

"The expansion of our RAS offerings into preclinical, statistics, and data management allows us to compete for business in a much larger market than the regulatory clinical PK/PD needs we currently serve," Dr. Murphy says.

In other company news, Pharsight and CRI Worldwide are partnering to offer combined clinical services, including trial design, simulation, execution, analysis, and reporting.

The alliance provides a broader solution to customers and addresses the growing need for drug-development companies to improve efficiency in their performance and analysis of clinical trials. Through their partnership, Pharsight and CRI can provide clients with faster delivery of results, a more informative trial, and a higher likelihood of success.

According to Ken King, CEO of CRI Worldwide, there is value in linking CRI's clinical-trial execution capabilities with Pharsight's state-of-the-art design, analysis, and reporting expertise.

"Our alliance with CRI allows us to get involved earlier in the process when the client is contracting with the clinic and the trial is still being designed," says Shawn O'Connor, president, CEO, and chairman of Pharsight. "On the back end, we are working with CRI to ensure seamless data transfers and rapid turnaround of regulatory analysis and reporting."

***Our alliance with CRI allows us to get involved earlier in the process when the client is contracting with the clinic and the trial is still being designed, says Shawn O'Connor, President, CEO, and Chairman of Pharsight.***



***Clients can expect faster delivery of results, a more informative trial, and a higher likelihood of success, says Ken King, CEO of CRI Worldwide.***

